Please forward this error screen to sharedip-1666228125. Bs grewal pdf download forward this error screen to sharedip-23229188100. BACKGROUND AND OBJECTIVE: The mainstay of treatment for acute bronchiolitis remains supportive care. Studies selected were randomized or quasi-randomized controlled trials comparing nebulized HS with 0.
RESULTS: We included 24 trials involving 3209 patients, 1706 of whom received HS. Hospitalized patients treated with nebulized HS had a significantly shorter length of stay compared with those receiving 0. No significant adverse events related to HS inhalation were reported. CONCLUSIONS: Nebulized HS is a safe and potentially effective treatment of infants with acute bronchiolitis. The mainstay of treatment for acute bronchiolitis remains supportive care.
We included 24 trials involving 3209 patients, 1706 of whom received HS. Nebulized HS is a safe and potentially effective treatment of infants with acute bronchiolitis. Bronchiolitis in US emergency departments 1992 to 2000: epidemiology and practice variation. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Acute viral bronchiolitis in children- a very common condition with few therapeutic options.
Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. Effectiveness of nebulized hypertonic saline and epinephrine in hospitalized infants with bronchiolitis. Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis. Nebulized hypertonic saline solution for acute bronchiolitis in infants. The tale of 2 trials: disentangling contradictory evidence on hypertonic saline for acute bronchiolitis. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial. Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. Hypertonic saline in acute bronchiolitis: a randomized controlled trial. Utility of hypertonic saline in the management of acute bronchiolitis in infants: a randomized controlled study. Aerosol therapy in infants and toddlers: past, present and future. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Due to the popularity of the AAP Virtual Career Fair, there’s a new Winter event Wednesday, January 31 through Thursday, February 1.
This article has a correction. Zhang et al, Nebulized Hypertonic Saline for Acute Bronchiolitis: A Systematic Review. 472 in 2010 and 2011. Globally, it has been estimated that, in 2005, at least 33. 5 years, with incidence in developing countries more than twice that of industrialized countries.
Despite its high incidence and morbidity, there are few effective therapies for acute bronchiolitis in infancy, and the mainstay of treatment remains supportive care. HS administered via nebulizer has been proposed as a potentially effective therapy for acute bronchiolitis in infants. 65 outpatients with acute bronchiolitis, as compared with 0. Over the past decades, a growing number of randomized trials have been undertaken to assess the effects and safety of nebulized HS in infants with acute bronchiolitis. Since then, new trials with conflicting results have been published, and an updated synthesis of the literature is needed. We decided to conduct a new systematic review of currently available randomized trials to assess the efficacy and safety of nebulized HS in infants with acute bronchiolitis and to explore possible reasons for inconsistent results across trials. We hypothesize that nebulized HS may be less effective than previously claimed for acute bronchiolitis and effect size of HS may mainly depend on diagnostic accuracy of bronchiolitis and the treatment regimen.